Login to Your Account



Psoriasis and PIM-1

Deep data dive reveals skin-deep target

By Anette Breindl
Science Editor

Friday, February 14, 2014
Researchers have developed an innovative approach to integrating genomic data with research on animal models, and used it to identify a potential new target for treating psoriasis. Psoriasis is an inflammatory skin condition which affects more than a million people in the U.S. Ten percent of patients with psoriasis use biologics – mainly TNF-blockers such as Enbrel (etanercept, Amgen Inc.), Humira (adalimumab, Abbvie Inc.), Remicade (infliximab, Johnson & Johnson) and Simponi (golimumab, Janssen Biotech Inc.). Experimental drugs also target cytokines such as IL-17 and IL-23. The target, the kinase PIM1, is induced by the inflammatory cytokine interleukin-22 (IL-22).

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription